A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Phase 2 Completed 449 enrolled Ophthotech Corporation

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study are to evaluate the safety and efficacy of E10030 intravitreous injection when administered in combination with Lucentis® against a control of Lucentis® alone in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

Timeline

Start: 2010-03
Primary completion: 2012-06
Completion: 2012-06

Publications

Park EJ, Choi J, Lee KC, Na DH. Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs. 2019 Jun;24(2):107-119. doi: 10.1080/14728214.2019.1604684. Epub 2019 Apr 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PEGPLERANIB SODIUM	Aptamer	0.3 mg	Intravitreal
Subject	PEGPLERANIB SODIUM	Aptamer	1.5 mg	Intravitreal
Comparator	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Summary

Timeline

Publications

Drugs

Indications